SWOG clinical trial number
S0111
A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) (IND 59699) Administered Every 21 Days in Patients with Hormone Refractory Prostate Cancer
Closed
Phase
Accrual
100%
Published
Research committees
Genitourinary Cancer
Treatment
BMS-247550
Eligibility Criteria Expand/Collapse
Pt must have histologic adenocarcinoma of the prostatewhich is measurable or evaluable Stage D1 or D2. Pts must have metastatic PCa deemed unresponsive or refractory to hormone therapy by criteria in Section 5.2 of the protocol. PSA >/= 5 ng/ml w/in 14 days prior to registration. Mx disease w/in 28 days; non-mx disease w/in 42 days. Pt must have baseline serum sample and agree to have submitted per Section 15.2. CT abd/pelvis w/in 28 days, bone scan w/in 42. Castrated & willing to continue/restart LHRH. At least 28 days out from flutamide or ketoconazole, 42 for bicalutamide or nilutamide. Prior RT >/=28 days prior to reg and to < 30% of bone marrow okay. No prior strontium or samarium. No prior chemo. One prior biologic. PS 0-2. AGC >/= 1500, PLT >/= 100,000, bili </= IULN, SGOT/SGPT </= 2.5 x IULN, creat </= 2.0 or CalcCrCl >/= 40 w/in 7 days. No unconventional therapy (St. John's Wort, PC-SPES). Not planning to begin bisphosphonates. No hx of brain mets.
Publication Information Expand/Collapse
2009
Cooperative group trials - Southwest Oncology Group (SWOG) innovations in advanced prostate cancer [PMID21085622; PMC2981166]
2005
Ixabepilone (epothilone b analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111
2004
Epothilone B (Epo-B) analogue BMS-247550 (NSC# 710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). a Southwest Oncology Group study (S0111)
Other Clinical Trials
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase